Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab. Ravulizumab, a new long-acting C5 inhibitor with a four times longer mean half-life than eculizumab...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Main Authors: Brodsky, Robert A., de Latour, Régis Peffault, Rottinghaus, Scott T., Röth, Alexander, Risitano, Antonio M., Weitz, Ilene C., Hillmen, Peter, Maciejewski, Jaroslaw P., Szer, Jeff, Lee, Jong Wook, Kulasekararaj, Austin G., Volles, Lori, Damokosh, Andrew I., Ortiz, Stephan, Shafner, Lori, Liu, Peng, Hill, Anita, Schrezenmeier, Hubert
Formato: Artigo
Idioma:Inglês
Publicado: Fondazione Ferrata Storti 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776354/
https://ncbi.nlm.nih.gov/pubmed/31949012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.236877
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares